FIELD: biotechnologies.
SUBSTANCE: invention describes the isolated molecule of nucleinic acid coding the mutant polypeptide BRAF where the mutations provide resistance to BRAF inhibitors. The present invention also describes the isolated mutant polypeptide BRAF coded by the named molecule of nucleinic acid, the expressing vector containing the named molecule of nucleinic acid, the host cell for expressing of the named mutant polypeptide BRAF and the method of obtaining of the named mutant polypeptide BRAF by cultivation of the named host cell. Using the version of mutant polypeptide BRAF according to the present invention, the methods of determination of the compound which is the second generation BRAF inhibitor by the level of phosphorylation of BRAF substratum or cellular proliferation in the cell containing BRAF substratum. The present invention describes the method of screening of the subject with malignant tumour for presence of BRAF mutation providing resistance to treatment by RAF inhibitor.
EFFECT: invention allows to find new BRAF inhibitors which can be used for treatment of the patients with resistance to BRAF inhibitors.
21 cl, 8 dwg, 3 ex
| Title |
Year |
Author |
Number |
| DETERMINATION OF CELL SENSITIVITY TO TREATMENT WITH B-Raf INHIBITOR BY DETECTION OF K-ras MUTATION AND LEVELS OF RTK EXPRESSION |
2010 |
- Khatzivassiliu Dzhordzhija
- Malek Shiva
|
RU2553379C2 |
| AGENT INDUCING CELL DEATH FOR CELLS HAVING BRAF GENE MUTATIONS, AGENT SUPPRESSING GROWTH OF SUCH CELLS, AND PHARMACEUTICAL COMPOSITION FOR THE THERAPY OF DISEASES CAUSED BY GROWTH DEFECT OF SUCH CELLS |
2016 |
- Nishita Hiroki
- Nisita Khiroki
|
RU2760835C2 |
| BRAF KINASE INHIBITOR N-(3-(5-(4-CHLOROPHENYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-CARBONIL)-2,4-DIFLUOROPHENYL)PROPANE-1-SULFONAMIDE |
2018 |
- Leonov Sergej Viktorovich
- Chuprov-Netochin Roman Nikolaevich
- Ivanenkov Yan Andreevich
|
RU2687107C1 |
| COMPOSITIONS AND METHODS OF TREATMENT OF CANCER WITH BRAF ATYPICAL MUTATIONS |
2018 |
- Decrescenzo, Gary
- Welsch, Dean
- Saha, Saurabh
|
RU2812706C2 |
| THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR |
2017 |
- Caponigro, Giordano
- Meyer, Matthew John
- Cooke, Vesselina
- Stuart, Darrin
|
RU2774612C2 |
| APILIMOD COMPOSITIONS AND METHODS OF USING THEM IN TREATING COLORECTAL CANCER |
2015 |
- Bikharri Nil
- Gejl Sofiya
- Landrette Shon
- Bekett Pol
- Konrad Kris
- Syuj Tyan
- Ernandes Marilens
- Rotberg Dzhonatan M.
- Likhenshtejn Khenri
|
RU2739992C2 |
| COMPOSITIONS BASED ON SHP2 INHIBITOR AND METHODS OF CANCER TREATMENT |
2018 |
- Nichols, Robert J.
- Goldsmith, Mark A.
- Schulze, Christopher
- Smith, Jacqueline
- Wildes, David E.
- Kelsey, Stephen
- Singh, Mallika
|
RU2805355C2 |
| COMBINATION THERAPY |
2018 |
|
RU2815400C2 |
| METHOD FOR PROLIFERATIVE DISEASE TREATMENT |
2012 |
- Styuart Darrin
- Tkhakur Megkhna Das
|
RU2622015C2 |
| COMPOSITIONS AND METHODS FOR TARGET ELIMINATION OF MUTATION ESCAPE IN TARGET CANCER THERAPY |
2008 |
- Ehjpelian Dehvid
- Frantsuzoff Aleks
- Rodell Timoti K.
|
RU2505313C2 |
